Major Depressive Disorders Clinical Trial
Official title:
Efficacy of Transcranial Direct Current Stimulation (tDCS) of Dorsolateral-prefrontal Cortex as an Add-on Treatment for Drug-naïve Major Depressive Disorder: A Randomized, Double-blind, Sham-controlled Trial
The aim of this study is to assess the efficacy of Transcranial Direct Current Stimulation (tDCS) as an Add-on Treatment for the drug-naïve Major depressive disorder. Meanwhile, evaluate the effect of tDCS on cognitive function of drug-naïve MDD patients. Furthermore, the investigators will examine the changes in cortisol, gut microbiome and some biomarkers. The hypothesis of this study is that tDCS alleviate the depressive symptoms and improve the cognitive function of drug-naïve Major depressive disorder patients with regulating inflammatory response.
This is a randomized, double-blind, sham-controlled study using transcranial Direct Current Stimulation (tDCS) for 4-week treatment. After the intervention of tDCS, there is a follow up visit at week 8 in order to understand the long-term effects of tDCS. Participants were randomly assigned 1:1 to tDCS group or sham-control group. Active tDCS comprised 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks. Sham was administered similarly, but with current turned off after 30s. Apart from studying the effects of tDCS on severity of depression and cognitive function, the secondary outcomes are to examine biomarkers related to inflammatory activity. Scale assessments are performed before the initiation of treatment, week 1, week 2, week 3, week 4 and week8. Collection of blood, excrement and saliva takes place at three time points, at the baseline, week 4 and week 8. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02972398 -
N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders
|
N/A | |
Completed |
NCT00855530 -
Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT00825019 -
Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine
|
Phase 3 | |
Completed |
NCT02829671 -
Loneliness and Occurrence of Suicide Attempts and Suicidal Ideas
|
N/A | |
Recruiting |
NCT02681822 -
Multi-center Imaging Genetics Studies in China
|
||
Completed |
NCT00825058 -
Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
|
Phase 3 | |
Completed |
NCT01347138 -
Health Care Management for the Elderly in Community Through Screening
|
N/A | |
Completed |
NCT01377896 -
The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours
|
N/A | |
Completed |
NCT02449447 -
Blended Depression Therapy: Cognitive Behaviour Therapy Face-to-face and Via Internet
|
N/A | |
Completed |
NCT06239740 -
Effects of Electroacupuncture on Cognitive Symptoms in Major Depressive Disorder
|
N/A | |
Not yet recruiting |
NCT02942251 -
Relapse Predicting Model for First Episode Depression
|
N/A | |
Recruiting |
NCT02590185 -
MetAbolism vaRiability of VEnLafaxine
|
N/A |